TG Therapeutics to Host Conference Call on Second Quarter 2022 Financial Results and Business Update
TG Therapeutics (NASDAQ: TGTX) has announced a conference call scheduled for August 8, 2022, at 8:30 AM ET to discuss its second-quarter financial results. The call will be led by Michael S. Weiss, Executive Chairman and CEO. A press release detailing the financial results will be issued before the call. Participants can join the call by dialing 1-877-407-8029 (U.S.) or 1-201-689-8029 (international). A live webcast and audio recording of the call will be available on the company's website for 30 days post-event.
- Scheduled conference call indicates proactive communication with investors.
- CEO hosting call suggests transparency and leadership engagement.
- None.
Conference call to be held Monday, August 8, 2022 at 8:30 AM ET
NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, August 8, 2022 at 8:30 AM ET to discuss results for the second quarter of 2022. Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS). For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and Linkedin.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
What is the date and time of the TG Therapeutics conference call?
Who will lead the TG Therapeutics conference call?
How can I participate in the TG Therapeutics conference call?
Where can I find the TG Therapeutics financial results?
Will the TG Therapeutics conference call be available for replay?
